Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 555

1.

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.

2.

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.

Umansky V, Sevko A.

Cancer Immunol Immunother. 2012 Feb;61(2):275-282. doi: 10.1007/s00262-011-1164-6. Epub 2011 Nov 27.

PMID:
22120757
3.

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.

Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M, Umansky V.

J Invest Dermatol. 2013 Jun;133(6):1610-9. doi: 10.1038/jid.2012.444. Epub 2012 Dec 6.

4.

Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.

Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V.

J Immunol. 2013 Mar 1;190(5):2464-71. doi: 10.4049/jimmunol.1202781. Epub 2013 Jan 28.

5.

CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.

Umansky V, Blattner C, Gebhardt C, Utikal J.

Cancer Immunol Immunother. 2017 Aug;66(8):1015-1023. doi: 10.1007/s00262-017-1988-9. Epub 2017 Apr 5. Review.

PMID:
28382399
6.

Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.

Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG.

J Immunol. 2012 Jun 1;188(11):5365-76. doi: 10.4049/jimmunol.1103553. Epub 2012 Apr 23.

7.

Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.

Das SK, Guo C, Pradhan AK, Bhoopathi P, Talukdar S, Shen XN, Emdad L, Subler MA, Windle JJ, Sarkar D, Wang XY, Fisher PB.

Oncotarget. 2016 Jul 26;7(30):46848-46861. doi: 10.18632/oncotarget.10040.

9.

Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.

Karakhanova S, Yang Y, Link J, Soltek S, von Ahn K, Umansky V, Werner J, Bazhin AV.

Mol Immunol. 2013 Dec;56(4):649-59. doi: 10.1016/j.molimm.2013.06.021. Epub 2013 Aug 2.

PMID:
23911424
10.

Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.

Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.

Int J Cancer. 2014 Apr 15;134(8):1810-22. doi: 10.1002/ijc.28506. Epub 2013 Oct 21.

11.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

12.

T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma.

Lengagne R, Pommier A, Caron J, Douguet L, Garcette M, Kato M, Avril MF, Abastado JP, Bercovici N, Lucas B, Prévost-Blondel A.

PLoS One. 2011;6(5):e20235. doi: 10.1371/journal.pone.0020235. Epub 2011 May 25.

13.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A.

J Immunother. 2016 Nov/Dec;39(9):343-354.

PMID:
27741089
14.

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Serafini P, Mgebroff S, Noonan K, Borrello I.

Cancer Res. 2008 Jul 1;68(13):5439-49. doi: 10.1158/0008-5472.CAN-07-6621.

15.

Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A.

J Immunol. 2012 Dec 15;189(12):5602-11. doi: 10.4049/jimmunol.1201018. Epub 2012 Nov 14.

16.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

17.

Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.

Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf D, Umansky V.

J Immunol. 2009 Nov 15;183(10):6330-7. doi: 10.4049/jimmunol.0900609. Epub 2009 Oct 19.

18.

Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S.

PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/5c756e7d-6e97-416f-836a-dced97cf46af. Kar, Upendra [corrected to Kar, Upendra K].

19.

Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.

Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T.

J Innate Immun. 2014;6(3):293-305. doi: 10.1159/000355126. Epub 2013 Oct 29.

PMID:
24192491
20.

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

Supplemental Content

Support Center